X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PFIZER - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PFIZER BIOCON LTD/
PFIZER
 
P/E (TTM) x 87.0 33.3 261.1% View Chart
P/BV x 7.4 4.9 150.4% View Chart
Dividend Yield % 0.2 0.7 22.6%  

Financials

 BIOCON LTD   PFIZER
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
PFIZER
Mar-18
BIOCON LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1882,365 50.2%   
Low Rs3051,625 18.8%   
Sales per share (Unadj.) Rs68.7430.3 16.0%  
Earnings per share (Unadj.) Rs7.678.7 9.6%  
Cash flow per share (Unadj.) Rs14.093.2 15.0%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.11.0 13.4%  
Book value per share (Unadj.) Rs86.3586.5 14.7%  
Shares outstanding (eoy) m600.0045.75 1,311.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.6 234.3%   
Avg P/E ratio x98.925.3 390.0%  
P/CF ratio (eoy) x53.421.4 249.6%  
Price / Book Value ratio x8.63.4 254.2%  
Dividend payout %13.225.4 52.1%   
Avg Mkt Cap Rs m447,90091,271 490.7%   
No. of employees `0006.12.6 233.8%   
Total wages/salary Rs m9,3113,143 296.3%   
Avg. sales/employee Rs Th6,705.87,484.8 89.6%   
Avg. wages/employee Rs Th1,514.21,195.0 126.7%   
Avg. net profit/employee Rs Th736.91,369.1 53.8%   
INCOME DATA
Net Sales Rs m41,23419,685 209.5%  
Other income Rs m2,0621,143 180.4%   
Total revenues Rs m43,29620,828 207.9%   
Gross profit Rs m8,2915,003 165.7%  
Depreciation Rs m3,851663 581.3%   
Interest Rs m6154 14,642.9%   
Profit before tax Rs m5,8875,479 107.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,878 83.5%   
Profit after tax Rs m4,5313,601 125.8%  
Gross profit margin %20.125.4 79.1%  
Effective tax rate %26.734.3 77.7%   
Net profit margin %11.018.3 60.1%  
BALANCE SHEET DATA
Current assets Rs m41,48624,167 171.7%   
Current liabilities Rs m21,4139,544 224.4%   
Net working cap to sales %48.774.3 65.5%  
Current ratio x1.92.5 76.5%  
Inventory Days Days6455 116.1%  
Debtors Days Days9429 328.1%  
Net fixed assets Rs m50,6619,514 532.5%   
Share capital Rs m3,000458 655.7%   
"Free" reserves Rs m48,80826,375 185.1%   
Net worth Rs m51,80826,832 193.1%   
Long term debt Rs m17,89825 71,592.0%   
Total assets Rs m99,89736,900 270.7%  
Interest coverage x10.61,305.5 0.8%   
Debt to equity ratio x0.30 37,078.4%  
Sales to assets ratio x0.40.5 77.4%   
Return on assets %5.29.8 52.7%  
Return on equity %8.713.4 65.2%  
Return on capital %9.620.4 47.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05822 53,830.4%   
Fx outflow Rs m7,3481,489 493.6%   
Net fx Rs m4,710-1,466 -321.2%   
CASH FLOW
From Operations Rs m6,6213,318 199.5%  
From Investments Rs m-6,840-2,383 287.0%  
From Financial Activity Rs m-2,397-1,104 217.2%  
Net Cashflow Rs m-2,612-169 1,550.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 63.9 32.2%  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 4.9 218.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.7 84.0%  
Shareholders   109,995 85,207 129.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STRIDES SHASUN LTD  ELDER PHARMA  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Oct 17, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - CIPLA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS